ZA202002292B - Methods of treating heart failure with preserved ejection fraction - Google Patents
Methods of treating heart failure with preserved ejection fractionInfo
- Publication number
- ZA202002292B ZA202002292B ZA2020/02292A ZA202002292A ZA202002292B ZA 202002292 B ZA202002292 B ZA 202002292B ZA 2020/02292 A ZA2020/02292 A ZA 2020/02292A ZA 202002292 A ZA202002292 A ZA 202002292A ZA 202002292 B ZA202002292 B ZA 202002292B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- heart failure
- ejection fraction
- treating heart
- preserved ejection
- Prior art date
Links
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566668P | 2017-10-02 | 2017-10-02 | |
| PCT/IB2018/057648 WO2019069230A1 (en) | 2017-10-02 | 2018-10-02 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202002292B true ZA202002292B (en) | 2022-12-21 |
Family
ID=63963334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/02292A ZA202002292B (en) | 2017-10-02 | 2020-05-04 | Methods of treating heart failure with preserved ejection fraction |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11617754B2 (enExample) |
| EP (1) | EP3691650A1 (enExample) |
| JP (1) | JP2020536121A (enExample) |
| KR (1) | KR20200102982A (enExample) |
| CN (1) | CN111163782A (enExample) |
| BR (1) | BR112020006472A2 (enExample) |
| CA (1) | CA3078163A1 (enExample) |
| IL (1) | IL273723A (enExample) |
| MX (1) | MX2020003243A (enExample) |
| TW (1) | TW201924689A (enExample) |
| WO (1) | WO2019069230A1 (enExample) |
| ZA (1) | ZA202002292B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691650A1 (en) | 2017-10-02 | 2020-08-12 | Poxel | Methods of treating heart failure with preserved ejection fraction |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| CA3103324A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| CN121287190A (zh) * | 2021-09-07 | 2026-01-09 | 深圳迈瑞生物医疗电子股份有限公司 | 一种超声波数据的处理方法、成像装置 |
| CN116440075B (zh) * | 2023-06-01 | 2025-05-06 | 苏州中化药品工业有限公司 | 一种干混悬剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804113B1 (fr) | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| FR2853650B1 (fr) | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
| FR2896159B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| FR2896161B1 (fr) | 2006-01-13 | 2008-04-04 | Merck Sante Soc Par Actions Si | Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. |
| FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| DE102008007314A1 (de) | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten |
| US20110124860A1 (en) | 2008-05-23 | 2011-05-26 | Aubourg Stephanie | Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives |
| SI2344435T1 (sl) | 2008-07-29 | 2016-05-31 | Poxel | Proces izolacije enantiomernih spojin iz enantiomernih mešanic s kristalizacijo nadzorovano z velikostjo delcev |
| ES2530223T3 (es) | 2008-12-12 | 2015-02-27 | Poxel S.A.S. | Combinación de insulina con derivados de triazina y su uso para tratar la diabetes |
| JP5485292B2 (ja) | 2008-12-12 | 2014-05-07 | ポクセル・エスアーエス | Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物 |
| US8742102B2 (en) | 2009-03-26 | 2014-06-03 | Poxel | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| WO2011154496A1 (en) | 2010-06-09 | 2011-12-15 | Poxel | Treatment of type 1 diabetes |
| TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| EP2646422B1 (en) | 2010-12-01 | 2015-07-08 | Poxel | Separation of triazine derivatives enantiomers using tartaric acid |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| WO2014160524A1 (en) * | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Cardio- metabolic and cascular effects of glp-1 metabolites |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| WO2016077126A1 (en) | 2014-11-10 | 2016-05-19 | Merck Sharp & Dohme Corp. | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease |
| KR20230111262A (ko) * | 2016-03-16 | 2023-07-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 엠파글리플로진을 포함하는 약제학적 조성물 및 이의용도 |
| EP3691650A1 (en) | 2017-10-02 | 2020-08-12 | Poxel | Methods of treating heart failure with preserved ejection fraction |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
-
2018
- 2018-10-02 EP EP18792513.6A patent/EP3691650A1/en not_active Withdrawn
- 2018-10-02 KR KR1020207011597A patent/KR20200102982A/ko not_active Ceased
- 2018-10-02 WO PCT/IB2018/057648 patent/WO2019069230A1/en not_active Ceased
- 2018-10-02 JP JP2020539153A patent/JP2020536121A/ja active Pending
- 2018-10-02 CA CA3078163A patent/CA3078163A1/en active Pending
- 2018-10-02 MX MX2020003243A patent/MX2020003243A/es unknown
- 2018-10-02 TW TW107134796A patent/TW201924689A/zh unknown
- 2018-10-02 CN CN201880063705.4A patent/CN111163782A/zh active Pending
- 2018-10-02 US US16/652,911 patent/US11617754B2/en active Active
- 2018-10-02 BR BR112020006472-6A patent/BR112020006472A2/pt not_active IP Right Cessation
-
2020
- 2020-03-31 IL IL273723A patent/IL273723A/en unknown
- 2020-05-04 ZA ZA2020/02292A patent/ZA202002292B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3691650A1 (en) | 2020-08-12 |
| CN111163782A (zh) | 2020-05-15 |
| IL273723A (en) | 2020-05-31 |
| US20200316078A1 (en) | 2020-10-08 |
| CA3078163A1 (en) | 2019-04-11 |
| US11617754B2 (en) | 2023-04-04 |
| KR20200102982A (ko) | 2020-09-01 |
| JP2020536121A (ja) | 2020-12-10 |
| BR112020006472A2 (pt) | 2020-10-06 |
| MX2020003243A (es) | 2020-09-18 |
| WO2019069230A1 (en) | 2019-04-11 |
| TW201924689A (zh) | 2019-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3500330T3 (pl) | Zespoły cewnika z zaworem i powiązane sposoby | |
| EP3171786A4 (en) | Devices and methods for treating heart failure | |
| ZA201705673B (en) | Methods for treating skin | |
| IL253954B (en) | Implantable devices and related methods for heart failure monitoring | |
| IL274865A (en) | Treatment methods with asparaginase | |
| SMT202500067T1 (it) | Metodi per trattare l'insufficienza cardiaca con attivatori del sarcomero cardiaco | |
| IL273723A (en) | Methods for the treatment of heart failure with preserved ejection fraction | |
| ZA201706257B (en) | Treatment of wood | |
| SG10201503314VA (en) | Valved catheter assemblies and related methods | |
| IL267253A (en) | Methods for treating cochlear synaptopathy | |
| EP3207940A4 (en) | Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure | |
| IL251852A0 (en) | Systems and methods for treating the heart valve | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| PL3352745T3 (pl) | Połączenie dofetylidu i meksyletyny w zapobieganiu i leczeniu migotania przedsionków | |
| IL276577A (en) | Methods for treating cardiac injury | |
| SG11201704780UA (en) | Method for treating heart failure | |
| IS050183A (en) | Method of tissue preservation | |
| IL270819A (en) | Methods for the treatment of chronic pouchitis | |
| EP3256137A4 (en) | Method of treating heart failure | |
| GB201514303D0 (en) | Bifidobacteria for treating cardiac conditions | |
| PL3544624T3 (pl) | Leczenie niedywolności serca i niedokrwiennego uszkodzenia reperfuzyjnego serca | |
| EP3089725A4 (en) | Method and system for heart pacing | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| GB201514302D0 (en) | Lactobacilli for treating cardiac dysfunction | |
| GB201510481D0 (en) | Artificial heart |